Executive shakeup at Vera Therapeutics (VERA) as new Chief Regulatory Officer named
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Vera Therapeutics, Inc. is changing its regulatory leadership. Effective August 3, 2026, Nancy Bowman, M.D., Ph.D. will become the company’s Chief Regulatory Officer. On the same date, current Chief Regulatory Officer William Turner will step down from that role and move into a new position as Special Advisor for Regulatory Affairs.
The company disclosed this leadership transition under the category covering departures and appointments of certain officers.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Effective date of role changes: August 3, 2026
Announcement date: July 9, 2026
Par value per share: $0.001 per share
3 metrics
Effective date of role changes
August 3, 2026
Date when CRO and advisor roles take effect
Announcement date
July 9, 2026
Date company announced the officer transition
Par value per share
$0.001 per share
Class A common stock par value
Key Terms
Chief Regulatory Officer, Special Advisor for Regulatory Affairs, Emerging growth company, Section 12(b) of the Act
4 terms
Chief Regulatory Officer financial
"will succeed Mr. Turner as the Company’s Chief Regulatory Officer, effective as of August 3, 2026"
Special Advisor for Regulatory Affairs financial
"will transition to the role of Special Advisor for Regulatory Affairs, effective as of August 3, 2026"
Emerging growth company regulatory
"Emerging growth company Item 5.02 Departure of Directors or Certain Officers"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Section 12(b) of the Act regulatory
"Securities registered pursuant to Section 12(b) of the Act"
FAQ
What leadership change did Vera Therapeutics (VERA) announce in this 8-K?
Vera Therapeutics announced a regulatory leadership transition. William Turner will leave the Chief Regulatory Officer role and become Special Advisor for Regulatory Affairs, while Nancy Bowman, M.D., Ph.D., will assume the Chief Regulatory Officer position effective August 3, 2026.
Who is becoming Chief Regulatory Officer at Vera Therapeutics (VERA)?
Nancy Bowman, M.D., Ph.D., will become Chief Regulatory Officer at Vera Therapeutics. She is scheduled to assume the role effective August 3, 2026, succeeding William Turner, who will move to a Special Advisor for Regulatory Affairs position on the same date.
What happens to current Chief Regulatory Officer William Turner at Vera Therapeutics (VERA)?
William Turner will transition from Chief Regulatory Officer to Special Advisor for Regulatory Affairs. This change takes effect August 3, 2026, allowing him to continue contributing regulatory expertise to Vera Therapeutics while Nancy Bowman, M.D., Ph.D., takes over the Chief Regulatory Officer role.
When does the officer transition at Vera Therapeutics (VERA) become effective?
The officer transition becomes effective on August 3, 2026. On that date, Nancy Bowman, M.D., Ph.D., will assume the Chief Regulatory Officer role, and William Turner will move into the position of Special Advisor for Regulatory Affairs at Vera Therapeutics.
Under which item did Vera Therapeutics (VERA) disclose this management change?
The management change was disclosed under Item 5.02, which covers departures and appointments of directors and certain officers. This item is used when companies report executive changes such as role transitions, promotions, or departures that may be important to shareholders.